Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

2026-02-25 - 13:43

VANCOUVER, British Columbia & GRAPEVINE, Texas -- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of ZUNVEYL® in the Long-Term Care (LTC) setting. Read More